The most far-fetched theories of post-finasteride syndrome

The two most far-fetched theories of post-finasteride syndrome were proposed by a dermatologist and a hair transplant surgeon. Physicians in these specialties tend to fervently deny that the syndrome is a valid medical condition, pointing instead to co-occurring conditions such as diabetes, anxiety, depression or, according to the theories below, delusions or sleep apnea. Theory … Read more

Medical journals and physicians ignore conflicts of interest after a few years

Physician-researchers known as key opinion leaders have a crucial role in launching a drug into the marketplace. While Propecia litigation was underway in the 2010s, a number of opinion leaders who had helped Merck launch Proscar and Propecia wrote articles defending the drug’s safety.

Firsthand experiences XIII: Recent reviews on Drugs.com & Ask a Patient

More reviews have been posted online since a compilation was published in 2023. While some are positive, others are alarming and consistent with adverse event reports submitted to FDA as well as media reports and some research. Find recent negative reviews from the Drugs.com and Ask a Patient websites below. Emphasis has been added in … Read more

New bibliography of case reports and series

A new bibliography of case reports & series is available. The papers come from a wide range of medical specialties including dermatology, hematology, hepatology, neurology, ophthalmology, pediatrics and andrology. Most were already in the main bibliography, but a few new ones were discovered. View the new bibliography: Case reports & series

Reckoning with underreporting—response to Lauck et al, 2024

We do not know if the medical records used in this study are sensitive to sexual dysfunction in healthy men, and especially in men taking these drugs for hair loss. Since the study includes men taking 5-ARIs, the results do not shed light on why sexual dysfunction might persist after stopping these drugs.

Study of depression from prostate drugs loses the signal by including past users

This study fails to assess the risk of depression associated with using finasteride or dutasteride because past users of 5-ARIs were counted as cases. 37% of cases in the 5-ARI group had stopped taking the drug 181 days or more prior to initial diagnosis or treatment for depression. Only slightly more than half of cases were current users at the time of initial diagnosis or treatment for depression. Moreover, the control group was taking ⍺-blockers.